Industry news that matters to you.  Learn more

Archives for March 2011

Aptiv Solutions and Cancer Genetics Partner, Focus On Cancer Clinical Trials

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics. Aptiv Solutions provides a portfolio of innovative services including adaptive trial design, early phase product strategy, regulatory services, pharmacovigilance, and the operational support of a global clinical research organization. CGI provides disease-specific biomarker knowledge, proprietary molecular testing and oncology lab services to sponsor companies during the early stages of clinical trials.

Cell Signaling Technology Announces License in Personalized Cancer Diagnostics

Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced last week that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor (EGFR) mutations for the field of tissue-based in vitro diagnostic testing. Mutant forms of EGFR are important determinants in the clinical management of lung cancer.

Rules-Based Medicine Launches OncologyMAP to Advance Cancer-Related Drug and Diagnostic Development

Rules-Based Medicine, Inc. (RBM), a leading provider of innovative biomarker solutions, today formally announced the global launch of OncologyMAP®, a powerful tool developed at the direction of and with funding from the National Cancer Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP® provides researchers with unprecedented data on biological pathways that could hold the key to understanding the molecular basis of cancer. OncologyMAP® was released to a limited number of key customers in October, and RBM has received positive feedback from clients who report valuable results in their studies for drug re-tasking, indication expansion, and patient stratification using this cost-effective, comprehensive testing service.

Plasma Biomarkers in Liver Cancer Refine Stratification of Patient Risk

According to an Internal Medicine News report, data presented at the 2011 Gastrointestinal Cancers Symposium at the American Society of Clinical Oncology meeting on gastrointestinal cancers in January sponsored by the American Society of Clinical Oncology suggests that a simple blood test may improve on systems conventionally used to estimate prognosis in patients with hepatocellular carcinoma.

Quest Diagnostics to Acquire Celera

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world’s pioneers in genetic diagnostics discovery and development, announced last week that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.